These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23809816)

  • 1. Plasmapheresis in healthy donors in the Netherlands: cohort study of risk factors for donor complications.
    Wiersum-Osselton JC; Marijt-van der Kreek T; van Dongen R
    Transfus Apher Sci; 2013 Apr; 48(2):163. PubMed ID: 23809816
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
    Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
    Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blood coagulation and fibrinolysis in blood donors after plasmapheresis].
    Zukowska B; Kotschy M
    Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):120-2. PubMed ID: 1437797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.
    Buzza M; Marks DC; Capper H; Cassin E; Badcock CA; Reid S; Kwok M; Yang H; Lee J; Corrigan C; Hartkopf-Theis T; Keller A
    Transfusion; 2012 Aug; 52(8):1806-13. PubMed ID: 22348664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An extensive study of donor plasmapheresis using a membrane method by the special study group of the Japanese Red Cross Society.
    Ikeda H; Tomono T; Sakai E; Endo N; Yokoyama S; Ogawa M; Shiraki H; Kameko S; Sekiguchi S
    Prog Clin Biol Res; 1990; 337():503-6. PubMed ID: 2112757
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor safety in plasmapheresis.
    Lundsgaard-Hansen P
    Dev Biol Stand; 1980; 48():287-95. PubMed ID: 7274560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current plasmapheresis practices in the United States.
    Crispen JF
    Dev Biol Stand; 1980; 48():297-301. PubMed ID: 7274561
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticoagulation, bleeding, and clotting at donor plasmapheresis.
    Evers J; Taborski U
    J Clin Apher; 2018 Aug; 33(4):538-540. PubMed ID: 29575131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial on the safety of long-term intensive plasmapheresis in donors.
    Bechtloff S; Tran-My B; Haubelt H; Stelzer G; Anders C; Hellstern P
    Vox Sang; 2005 Apr; 88(3):189-95. PubMed ID: 15787729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis and clotting activation.
    Vrielink H; Karssing W; de Korte D; Koopman R
    Transfus Apher Sci; 2013 Apr; 48(2):157. PubMed ID: 23809813
    [No Abstract]   [Full Text] [Related]  

  • 12. Observation of the changes of plasma proteins after long term plasmapheresis.
    Grgicević D; Pistotnik M; Pende B
    Dev Biol Stand; 1980; 48():279-86. PubMed ID: 6168506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions in healthy blood donors undergoing plasmapheresis.
    Schroeder ML; Buskard N; Herbert M; Kelton J; Rock G; Sternbach M
    Prog Clin Biol Res; 1990; 337():485-6. PubMed ID: 2353009
    [No Abstract]   [Full Text] [Related]  

  • 14. [The electrolyte content of donor blood in frequently repeated plasmapheresis].
    Gutnik RB; Zinevich AK
    Vrach Delo; 1968 Feb; 2():150-1. PubMed ID: 5669350
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of commercial plasmapheresis banks on the AIDS epidemic in Mexico.
    Volkow P; Perez-Padilla R; del-Rio C; Mohar A
    Rev Invest Clin; 1998; 50(3):221-6. PubMed ID: 9763887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional standards for human blood and blood products; source plasma (human)--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Nov; 46(226):57480-1. PubMed ID: 10253366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The apheresis: plasmapheresis, plateletpheresis, leukapheresis. Physiopathology of the donor (author's transl)].
    Avanzi G
    Pathologica; 1978; 70(1007-1008):467-80. PubMed ID: 370755
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma collection and donor safety in rural China.
    Dodd RY
    J Infect Dis; 2005 Nov; 192(10):1681-2. PubMed ID: 16235163
    [No Abstract]   [Full Text] [Related]  

  • 19. Maximum donation volumes per session in donor plasmapheresis.
    Karger R; Kretschmer V
    Vox Sang; 2006 Nov; 91(4):350; author reply 351-2. PubMed ID: 17105614
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasmapheresis operations in the United States--1968.
    Hartney JB
    JAMA; 1970 Aug; 213(6):1023-5. PubMed ID: 5468172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.